BCN Biosciences focuses on early-phase biotechnology development within the oncology drug discovery market. The company specializes in the development and commercialization of both small molecule and biological therapeutic drug candidates for cancer treatment. Additionally, BCN Biosciences is advancing technologies for early-stage cancer detection.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to systemic toxicity and reduced efficacy due to off-target effects. The development of targeted therapies and personalized medicine approaches is hindered by the complexity of cancer biology and the need for more selective drug delivery mechanisms.
Solution
BCN Biosciences is developing novel monoclonal antibodies (mAbs) against endothelial-derived targets to treat cancer. Their lead candidate, B303, is undergoing preclinical studies. BCN Biosciences is also developing small molecule drugs that can protect normal human tissues from radiation damage, in collaboration with the University of California Los Angeles and the Center for Medical Countermeasures against Radiation Risk (CMCR). The company focuses on identifying and validating new endothelial-derived gene products as therapeutic targets and building a portfolio of early-stage anticancer therapeutics.
Target Audience
The primary target audience includes biotech and pharmaceutical companies seeking research and drug development collaborations in the oncology space.
Features
- Development of monoclonal antibodies against endothelial-derived drug targets.
- Lead candidate B303 is moving into definitive preclinical studies.
- Researching small molecule drugs for radio-mitigation in collaboration with UCLA and CMCR.
- Screening proprietary libraries with phenotypic endpoints such as cellular clonogenic survival and DNA damage.